Principal Financial Group Inc. Has $4.86 Million Stock Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Principal Financial Group Inc. boosted its holdings in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) by 4.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 257,733 shares of the company’s stock after buying an additional 10,306 shares during the quarter. Principal Financial Group Inc.’s holdings in Pacira BioSciences were worth $4,856,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in the stock. Caitlin John LLC grew its stake in shares of Pacira BioSciences by 1,850.0% in the fourth quarter. Caitlin John LLC now owns 1,872 shares of the company’s stock worth $35,000 after acquiring an additional 1,776 shares during the last quarter. Nisa Investment Advisors LLC boosted its stake in Pacira BioSciences by 495.3% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company’s stock valued at $62,000 after buying an additional 2,749 shares in the last quarter. Virtus Investment Advisers Inc. acquired a new stake in shares of Pacira BioSciences during the 3rd quarter worth about $98,000. Quest Partners LLC increased its holdings in shares of Pacira BioSciences by 137.6% during the third quarter. Quest Partners LLC now owns 9,410 shares of the company’s stock worth $142,000 after buying an additional 5,449 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its position in Pacira BioSciences by 10.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 9,790 shares of the company’s stock valued at $184,000 after purchasing an additional 918 shares during the last quarter. 99.73% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research firms have issued reports on PCRX. Needham & Company LLC upped their price objective on Pacira BioSciences from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Friday. Barclays lifted their price objective on Pacira BioSciences from $17.00 to $24.00 and gave the company an “overweight” rating in a report on Friday. Royal Bank of Canada reissued a “sector perform” rating and issued a $18.00 price target on shares of Pacira BioSciences in a research note on Tuesday, January 14th. HC Wainwright boosted their target price on Pacira BioSciences from $57.00 to $70.00 and gave the company a “buy” rating in a research note on Friday. Finally, Truist Financial raised Pacira BioSciences from a “sell” rating to a “hold” rating and lifted their target price for the company from $8.00 to $25.00 in a research report on Thursday, January 30th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $27.22.

Pacira BioSciences Price Performance

Shares of Pacira BioSciences stock opened at $22.96 on Tuesday. The company has a quick ratio of 1.89, a current ratio of 2.25 and a debt-to-equity ratio of 0.51. The stock has a market capitalization of $1.06 billion, a price-to-earnings ratio of -11.31 and a beta of 0.80. The company has a 50-day simple moving average of $23.23 and a two-hundred day simple moving average of $18.74. Pacira BioSciences, Inc. has a twelve month low of $11.16 and a twelve month high of $31.67.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.